Imunon, Inc.
IMNN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.01 | 0.00 | -0.00 |
| FCF Yield | -150.20% | -275.31% | -210.69% | -490.65% |
| EV / EBITDA | -0.44 | -0.14 | -0.18 | 0.46 |
| Quality | ||||
| ROIC | -355.38% | -140.09% | -67.09% | -29.04% |
| Gross Margin | 0.00% | 0.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 1.01 | 0.97 | 0.64 | 0.78 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | 0.00% | 0.00% |
| Free Cash Flow Growth | 3.03% | 16.65% | -41.30% | -5.74% |
| Safety | ||||
| Net Debt / EBITDA | 0.26 | 0.21 | 0.16 | 0.62 |
| Interest Coverage | 0.00 | -106.71 | -4.96 | -36.86 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -660.77 | 0.00 | 94.12 | 79.46 |